Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to learn more about a condition called 'unclassified hyperoxaluria'. People with this condition have large amounts of oxalate in their urine, which can cause kidney stones and kidney failure. We do not know what causes the high level of oxalate in the urine. In this study, we will evaluate absorption of a test dose of oxalate taken orally by measuring the amount of the test dose that is eliminated in the urine. We will compare the results of affected patients to healthy volunteers.


Clinical Trial Description

Participants' oxalate intake and output will be monitored and assessed over a 24 hour period. Participants will ingest a prescribed oxalate dose and urine oxalate will be monitored for the 24 hour study period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00588120
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 1
Start date December 1998
Completion date January 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02289755 - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Phase 2
Completed NCT02038543 - Hydroxyproline Influence on Oxalate Metabolism Phase 1/Phase 2
Completed NCT03095885 - A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria N/A
Recruiting NCT02780297 - Prospective Research Rare Kidney Stones (ProRKS)
Completed NCT01127087 - Oxazyme in Patients With Hyperoxaluria Phase 1/Phase 2
Not yet recruiting NCT05443932 - Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients Phase 4
Completed NCT04756024 - Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in Children
Completed NCT02503345 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones Phase 2
Completed NCT00199459 - Proteomic Study of Urinary Stone Disease N/A
Completed NCT04119765 - Plasma Oxalate in Patient With Short Bowel
Completed NCT02404701 - Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk N/A
Completed NCT00283387 - Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria Phase 2
Completed NCT00587041 - Use of Oral Probiotics to Reduce Urinary Oxalate Excretion Phase 1/Phase 2
Completed NCT04571359 - Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary Oxalate
Withdrawn NCT00280215 - Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria Phase 3